Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model
1996

Photodynamic Therapy for Ovarian Cancer

Sample size: 40 publication Evidence: moderate

Author Information

Author(s): BA Goff, J Blake, MP Bamberg, T Hasan

Primary Institution: Massachusetts General Hospital, Harvard Medical School

Hypothesis

Can photodynamic therapy using an OC125 immunoconjugate improve treatment outcomes for ovarian cancer in a murine model?

Conclusion

The study suggests that photodynamic therapy with an OC125 immunoconjugate may effectively manage advanced ovarian cancer, especially with multiple treatments.

Supporting Evidence

  • 40% of mice treated three times survived after 50 days compared to all control mice dying within that time frame.
  • Viable tumor cells were reduced to 5% of controls after three treatments.
  • Single treatment resulted in a 34% reduction in viable tumor cells but had a 50% treatment-related mortality.

Takeaway

This study tested a new way to treat ovarian cancer using light and special medicine that targets cancer cells, and it found that doing this multiple times helps more than just once.

Methodology

Mice were injected with ovarian cancer cells and treated with an immunoconjugate followed by light exposure to assess tumor cell viability and survival.

Limitations

The study was conducted in a murine model, which may not fully replicate human responses, and the treatment's effectiveness in humans remains to be established.

Participant Demographics

Balb/C nude mice were used in the study.

Statistical Information

P-Value

0.0006

Statistical Significance

p=0.0006

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication